Related Experiment Video
Updated: Jul 10, 2026
Investigating Angiogenesis on a Functional and Molecular Level by Leveraging the Scratch Wound Migration Assay and the Spheroid Sprouting Assay
Published on: May 31, 2024
Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay
Holger Weber1, James Claffey, Megan Hogan
1ProQinase GmbH Freiburg, Breisacher Str. 117, D-79106 Freiburg, Germany.
Abstract:
Titanocene dichloride and two of its derivatives (Titanocene Y and C) were tested on human umbilical vein endothelial cells (HUVEC) sprouting in a spheroid-based cellular angiogenesis assay in order to determine IC50 values of inhibition. Titanocene dichloride and Titanocene Y inhibited HUVEC sprouting in this angiogenesis assay with IC50 values of 19 microM and 4.9 microM, while Titanocene C surprisingly showed no inhibition. This classifies Titanocene dichloride as a purely anti-angiogenic anticancer drug and Titanocene C as a purely cytotoxic anticancer drug. On the other hand, Titanocene Y combines both favourable anticancer activities and seems to be the drug candidate of choice for further optimisation.
Insights
Titanocene dichloride and Titanocene Y show anti-angiogenic properties, while Titanocene C is cytotoxic. Titanocene Y, with dual anticancer activities, is a promising drug candidate for further development.
Area of Science:
- Oncology
- Biochemistry
- Cell Biology
Background:
- Angiogenesis is crucial for tumor growth and metastasis.
- Titanocene dichloride derivatives are explored for anticancer potential.
- Understanding their mechanisms is key for drug development.
Purpose of the Study:
- To evaluate the anti-angiogenic and cytotoxic effects of titanocene dichloride and its derivatives (Titanocene Y and C).
- To determine the IC50 values for inhibition of human umbilical vein endothelial cells (HUVEC) sprouting.
- To classify the anticancer activities of these compounds.
Main Methods:
- Utilized a spheroid-based cellular angiogenesis assay.
- Tested titanocene dichloride, Titanocene Y, and Titanocene C on HUVEC sprouting.
- Quantified inhibition using IC50 values.
Main Results:
- Titanocene dichloride and Titanocene Y inhibited HUVEC sprouting with IC50 values of 19 µM and 4.9 µM, respectively.
- Titanocene C demonstrated no significant inhibition in the angiogenesis assay.
- Titanocene dichloride acts as an anti-angiogenic agent, and Titanocene C as a cytotoxic agent.
Conclusions:
- Titanocene dichloride exhibits purely anti-angiogenic anticancer activity.
- Titanocene C displays purely cytotoxic anticancer activity.
- Titanocene Y possesses both anti-angiogenic and cytotoxic properties, making it a promising candidate for further anticancer drug development.
